Compare Iron Mountain Inc (IRM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs Sanofi SA — how do they compare? Iron Mountain Inc trades at $127.19 (market cap $36.96B), while Sanofi SA trades at $44.08 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 2.8× Iron Mountain Inc's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| IRM | SNY | |
|---|---|---|
Market Cap | $36.96B | $104.83B |
Sector | Real Estate | Health |
52-Week High | $133.06 | $52.34 |
52-Week Low | $78.86 | $41.33 |
Enterprise Value | $56.10B | $121.32B |
Dividend Yield | 2.78% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $124.38, up 0.45% for the day, with a bullish technical signal and strong recent earnings beats. The stock has rallied 30.2% over three months, supported by data center growth and recurring storage revenue. However, the company faces high debt levels, with a debt-to-asset ratio of 74.39% in 2024, and a P/E ratio of 134.59 suggests elevated valuation. Analyst consensus is bullish with a $138.67 price target, though the RSI_6 at 84.86 indicates potential overbought conditions near-term.
Outlook remains positive due to consistent earnings outperformance and data center expansion, but risks include significant leverage and declining paper storage demand. The stock offers a dividend yield with a recent $0.86 payment, yet investors should weigh high valuation multiples against growth prospects in a competitive information services sector.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
